Abstract
The availability of somatropin [recombinant human growth hormone (GH)] has revolutionized the treatment of short stature resulting from GH deficiency. It is also widely used as an adjunct in the treatment of other disorders which do not fit the definition of classic GH deficiency, such as intrauterine growth restriction, Turner syndrome, healthy children with short stature and skeletal dysplasias.
The widespread use and ready availability of GH treatment has prompted questions about its tolerability, rationality, and the psychological effects of long-term treatment, leading to several trials.
Early treatment of GH deficiency will allow the child to reach his or her genetic potential, although there continues to be marked variability in the criteria used to diagnose the deficiency, and in the treatment schedule, especially during puberty. Treatment has also been shown to have a beneficial effect on growth in children with chronic renal failure, with no adverse effects on the renal function. There are, however, no long-term data to determine final height, or randomized controlled studies to justify routine use of GH in conditions such as intrauterine growth restriction. It remains controversial in conditions such as Turner syndrome and achondroplasia, where the response to treatment is only moderate. Healthy children with short stature have not been shown to have a psychological disadvantage, again proving difficult to justify prolonged GH treatment for idiopathic short stature. Meticulous monitoring, long-term follow-up to adult or near-adult final height, and well-defined endpoints of treatment need to be better clarified. The metabolic effects of treatment on the patient’s lipid profile, bone mineral density, and muscle mass need careful documentation, especially with the high doses used in an already susceptible population such as low birthweight children and those with Turner syndrome. Lastly, the psychosocial impact of GH treatment, financial implications, and cost efficacy of treatment in an ever-increasing list of indications should be taken into consideration for rationalizing its use in future.
Similar content being viewed by others
References
Fradkin JE, Schonberger LB, Mills JL, et al. Creutzfeld-Jacob Disease (CJD) in pituitary growth hormone recipients in the United States. JAMA 1991; 265: 880–4
Chen E, Liao Y, Smith D, et al. The human growth hormone locus: nucleotide sequence, biology and evolution. Genomics 1989; 4: 479–97
Kojima M, Hosoda H, Date Y, et al. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 1999; 402(6762): 656–60
Martha PMJ, Gorman KM, Blizzard RM, et al. Endogenous growth hormone secretion and clearance rates in normal boys, as determined by deconvolution analysis: relationship to age, pubertal status and body mass. J Clin Endocrinol Metab 1992; 74: 336–44
Leung DW, Spencer SA, Cachianes G, et al. Growth hormone receptor and serum binding protein: purification, cloning and expression. Nature 1987; 330: 537–43
Phillips LS, Vassilopoulou-Sellin R. Somatomedins. N Engl J Med 1980; 302: 371–80
Blum WF, Albertsson-Wickland K, Rosberg S, et al. Serum levels of insulin like growth factor-1 (IGF-1) and IGF binding protein-3 (IGFBP-3) reflect spontaneous GH secretion. J Clin Endocrinol Metab 1993; 76: 1610–6
Consensus guidelines for the diagnosis and treatment of growth hormone (GH) deficiency in childhood and adolescents: summary statement of the GH Research Society. GH Research Society. J Clin Endocrinol Metab 2000; 85(11): 3990–5
Saggese G, Ranke MB, Saenger P, et al. Diagnosis and treatment of growth hormone deficiency in children and adolescents: towards a consensus. Horm Res 1998; 50: 320–40
Rose SR, Municchi G, Barnes KM, et al. Spontaneous growth hormone secretion increases during puberty in normal girls and boys. J Clin Endocrinol Metab 1991; 73: 428–35
Kerrigan JR, Rogol AD. The impact of gonadal steroid hormone action on growth hormone secretion during childhood and adolescence. Endocr Rev 1992; 13: 281–98
Attie K, Ramirez NR, Conte F, et al. The pubertal growth spurt in eight patients with true precocious puberty and growth hormone deficiency: evidence for a direct effect of the sex steroids. J Clin Endocrinol Metab 1990; 71: 975–81
Wit JM, Kamp GA, Rikken B. Spontaneous growth and response to growth hormone treatment in children with growth hormone deficiency and idiopathic short stature. Pediatr Res 1996; 39: 295–302
Ranke MB, Price DA, Albertsson-Wikland K, et al. Factors determining pubertal growth and final height in growth hormone treatment of idiopathic growth hormone deficiency. Horm Res 1997; 48: 62–71
Rappaport R, Mugnier E, Limoni C, et al. A 5-year prospective study of growth hormone (GH)-deficient children treated with GH before the age of 3 years. French Serono Study Group. J Clin Endocrinol Metab 1997; 82(2): 452–6
Blethen S, Baptista J, Kuntze J, et al. Adult height in growth hormone (GH)-deficient children treated with biosynthetic GH. The Genotech Study Group. J Clin Endocrinol Metab 1997; 82(2): 418–20
De Angelis R, di Natale B, Lukezic M, et al. Final height in idiopathic growth hormone deficient children after optimized rhGH treatment [abstract]. Horm Res 1997; 48: 149
Barsanti S, Saggese G. Final height in children with growth hormone deficiency treated with recombinant growth hormone [abstract]. Horm Res 1997; 48: 151
Darendeliler F, Hindmarsh PC, Brook CGD. Dose response curves for treatment with biosynthetic human growth hormone. J Endocrinol 1990; 125: 311–6
Stanhope R, Albanese A, Hindmarsh P, et al. The effects of growth hormone therapy on spontaneous sexual development. Horm Res 1992; 38Suppl. 1: 9–13
Mauras N, Attie KM, Reiter EO, et al. High dose recombinant human growth hormone (GH) treatment of GH-deficient patients in puberty increases near-final height: a randomised, multicenter trial. J Clin Endocrinol Metab 2000; 85(10): 3653–60
Saggese G, Cesaretti G, Andreani G, et al. Combined treatment with growth hormone and gonadotropin-releasing hormone analogues in children with isolated growth hormone deficiency. Acta Endocrinol (Copenh) 1992; 127(4): 307–12
Mericq M, Eggers M, Avila A, et al. Near final height in pubertal growth hormone (GH)-deficient patients treated with GH alone or in combination with luteiniz-ing hormone-releasing hormone analog: results of a prospective randomised trial. J Clin Endocrinol Metab 2000; 85(2): 569–73
Toublanc JE, Couprie C, Garnier P, et al. The effects of treatment combining an agonist of gonadotropin-releasing hormone with growth hormone in pubertal patients with isolated growth hormone deficiency. Acta Endocrinol (Copenh) 1989; 120(6): 795–9
Gibney J, Wallace J, Spinks T, et al. The effects of 10 years of recombinant human growth hormone (GH) in adult GH-deficient patients. J Clin Endocrinol Metab 1999; 84(8): 2596–602
Saggese G, Baroncelli G, Bertelloni S, et al. The effect of long term growth hormone (GH) treatment on bone mineral density in children with GH deficiency: role of GH in attainment of peak bone mass. J Clin Endocrinol Metab 1996; 81(8): 3077–83
Juul A, Bernasconi S, Chatelain P, et al. Diagnosis of growth hormone (GH) deficiency and the use of GH in children with growth disorders. Horm Res 1995; 51: 284–99
Hakeem V, Hindmarsh PC, Brook CG. Intermittent versus continuous administration of growth hormone treatment. Arch Dis Child 1993; 68(6): 783–4
Ranke MB. Growth in Turner’s syndrome. Acta Paediatr 1994; 83(3): 343–4
Lyon AJ, Preece MA, Grant DB. Growth curve for girls with Turner syndrome. Arch Dis Child 1985; 60(10): 932–5
Rao E, Weiss B, Fukami M, et al. Pseudoautosomal deletions encompassing a novel homeobox gene cause growth failure in idiopathic short stature and Turner syndrome. Nat Genet 1997; 16(1): 54–63
Rosenfeld RG, Frane J, Attie KM, et al. Six-year results of a randomized, prospective trial of human growth hormone and oxandrolone in Turner syndrome. J Pediatr 1992; 121(1): 49–55
Haeusler G, Schmitt K, Blumel P, et al. Growth hormone in combination with anabolic steroids in patients with Turner syndrome: effect on bone maturation and final height. Acta Paediatr 1996; 85(12): 1408–14
Chu CE, Paterson WF, Kelnar CJ, et al. Variable effect of growth hormone on growth and final adult height in Scottish patients with Turner’s syndrome. Acta Paediatr 1997; 86(2): 160–4
Taback SP, Collu R, Deal CL, et al. Does growth-hormone supplementation affect adult height in Turner’s syndrome? Lancet 1996; 348(9019): 25–7
Van den Broeck J, Massa GG, Attanasio A, et al. Final height after long-term growth hormone treatment in Turner syndrome. European Study Group. J Pediatr 1995; 127(5): 729–35
Stewart LA, Parmar MK. Meta-analysis of the literature or of individual patient data: is there a difference? Lancet 1993; 341(8842): 418–22
Chernausek SD, Attie KM, Cara JF, et al. Growth hormone therapy of Turner syndrome: the impact of age on estrogen replacement on final height. J Clin Endocrinol Metab 2000; 85(7): 2439–45
Cutfield W, Wilton P, Bennmarker H, et al. Incidence of diabetes mellitus and impaired glucose tolerance in children and adolescents receiving growth hormone treatment. Lancet 2000; 355(9204): 610–3
Saenger P. Metabolic consequences of growth hormone treatment in paediatric practice. Horm Res 2000; 53(1): 60–9
Albertsson-Wikland K, Wennergren G, Wennergren M, et al. Longitudinal follow-up of growth in children born small for gestational age. Acta Paediatr 1993; 82: 438–43
Albertsson-Wikland K, Karlberg J. Natural growth in children born small for gestational age with and without catch-up growth. Acta Paediatr Suppl 1994; 399: 64–71
Davies PS, Valley R, Preece MA. Adolescent growth and pubertal progression in the Silver-Russel syndrome. Arch Dis Child 1988; 63(2): 130–5
Ackland FM, Stanhope R, Eyre C, et al. Physiological growth hormone secretion in children with short stature and intrauterine growth retardation. Horm Res 1988; 30: 241–5
Albertsson-Wikland K. Growth hormone secretion and growth hormone treatment in children with intrauterine growth retardation. Acta Paediatr Scand 1989; 349 Suppl.: 35–41
Chatelain PG, Cauderay MC, de Zegher F, et al. Growth hormone secretion and sensitivity in children born small for gestational age. Acta Paediatr Suppl 1996; 417: 15–6
de Zegher F, Albertsson-Wikland K, Wilton P, et al. Growth hormone treatment of short children born small for gestational age: meta-analysis of four independent, randomized, controlled, multicentre studies. Acta Paediatr Suppl 1996; 417: 27–31
Fjellestad-Paulsen A, Czernichow P, Brauner R, et al. Three-year data from a comparative study with recombinant human growth hormone in the treatment of short stature in young children with intrauterine growth retardation. Acta Paediatr 1998; 87(5): 511–7
Job JC, Chaussain JL, Job B, et al. Follow-up of three years of treatment with growth hormone and of one post-treatment year, in children with severe growth retardation of intrauterine onset. Pediatr Res 1996; 39(2): 354–9
de Zegher F, Albertsson-Wikland K, Wollmann HA, et al. Growth hormone treatment of short children born small for gestational age: growth responses with continuous and discontinuous regimens over 6 years. J Clin Endocrinol Metab 2000; 85(8): 2816–21
Barker DJ. In utero programming of cardiovascular disease. Theriogenology 2000; 53(2): 555–74
Forsen T, Eriksson J, Tuomilehto J, et al. The fetal and childhood growth of persons who develop type 2 diabetes. Ann Intern Med 2000; 133(3): 176–82
Scharer K. Growth and development of children with chronic renal failure. Study group on pubertal development in chronic renal failure. Acta Paediatr Scand Suppl 1990; 366: 90–2
Schaefer F, Seidel C, Binding A, et al. Pubertal growth in chronic renal failure. Pediatr Res 1990; 28(1): 5–10
Tonshoff B, Cronin MJ, Reichert M, et al. Reduced concentration of serum growth hormone (GH)-binding protein in children with chronic renal failure: correlation with GH insensitivity. The European Study Group for Nutritional Treatment of Chronic Renal Failure in Childhood. The German Study Group for Growth Hormone Treatment in Chronic Renal Failure. J Clin Endocrinol Metab 1997; 82(4): 1007–13
Tonshoff B, Blum WF, Wingen AM, et al. Serum insulin-like growth factors (IGFs) and IGF binding proteins 1, 2, and 3 in children with chronic renal failure: relationship to height and glomerular filtration rate. The European Study Group for Nutritional Treatment of Chronic Renal Failure in Childhood. J Clin Endocrinol Metab 1995; 80(9): 2684–91
Rees L, Rigden SP, Ward G, et al. Treatment of short stature in renal disease with recombinant human growth hormone. Arch Dis Child 1990; 65(8): 856–60
Hokken-Koelega AC, Stijnen T, de Muinck Keizer-Schrama SM, et al. Placebo-controlled, double-blind, cross-over trial of growth hormone treatment in pre-pubertal children with chronic renal failure. Lancet 1991; 338(8767): 585–90
Fine RN, Kohaut E, Brown D, et al. Long-term treatment of growth retarded children with chronic renal insufficiency, with recombinant human growth hormone. Kidney Int 1996; 49(3): 781–5
Fine RN, Yadin O, Moulton L, et al. Five years experience with recombinant human growth hormone treatment of children with chronic renal failure. J Pediatr Endocrinol 1994; 7(1): 1–12
Ranke MB. Towards a consensus on the diagnosis of idiopathic short stature. Horm Res 1996; 45Suppl. 2: 64–6
Ranke MB, Grauer ML, Kistner K, et al. Spontaneous adult height in idiopathic short stature. Horm Res 1995; 44: 152–7
Rekers-Mombarg LT, Wit JM, Massa GG, et al. Spontaneous growth in idiopathic short stature. European Study Group. Arch Dis Child 1996; 75(3): 175–80
Cowell CT, Dietsch S, Greenacre P. Growth hormone therapy for 3 years: the OZGROW experience. J Paediatr Child Health 1996; 32(2): 86–93
Hopwood NJ, Hintz RL, Gertner JM, et al. Growth response of children with non-growth-hormone deficiency and marked short stature during three years of growth hormone therapy. J Pediatr 1993; 123(2): 215–22
Loche S, Cambiaso P, Setzu S, et al. Final height after growth hormone therapy in non-growth-hormone-deficient children with short stature. J Pediatr 1994; 125: 196–200
Hindmarsh PC, Brook CG. Final height of short normal children treated with growth hormone. Lancet 1996; 348(9019): 13–6
Buchlis JG, Irizarry L, Crotzer BC, et al. Comparison of final heights of growth hormone-treated vs. untreated children with idiopathic growth failure. J Clin Endocrinol Metab 1998; 83(4): 1075–9
Kawai M, Momoi T, Yorfiji T, et al. Unfavourable effects of growth hormone therapy on the final height of boys with short stature not caused by growth hormone deficiency. J Pediatr 1997; 130(2): 205–9
Balducci R, Toscana V, Mangiantini A, et al. Adult height in short normal adolescent girls treated with gonadotrophin-releasing hormone analog and growth hormone. J Clin Endocrinol Metab 1995; 80(12): 3596–600
Lanes R, Gunczler P. Final height after combined growth hormone and gonadotrophin-releasing hormone analogue therapy in short healthy children entering into normally timed puberty. Clin Endocrinol 1998; 49(2): 197–202
Pasquino A, Pucarelli I, Roggini M, et al. Adult height in short normal girls treated with gonadotrophin-releasing hormone analogs and growth hormone. J Clin Endocrinol Metab 2000; 85(2): 619–22
Skuse D, Gilmour J, Tian CS, et al. Psychosocial assessment of children with short stature. Acta Pediatr Suppl. 1994; 406: 11–6
Bellus GA, Hefferon TW, Ortiz de Luna RI, et al. Achondroplasia is defined by recurrent G380R mutations of FGFR3. Am J Hum Genet 1995; 56: 368–73
Appan S, Laurent S, Chapman M, et al. Growth and growth hormone therapy in hypochondroplasia. Acta Paediatr Scand 1990; 79(8–9): 796–803
Shohat M, Tick D, Barakat S, et al. Short-term recombinant human growth hormone treatment increases growth rate in achondroplasia. J Clin Endocrinol Metab 1996; 81(11): 4033–7
Acknowledgements
Dr Peter Hindmarsh is an adviser to the Medicines Control Agency, United Kingdom.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Mehta, A., Hindmarsh, P.C. The Use of Somatropin (Recombinant Growth Hormone) in Children of Short Stature. Pediatr-Drugs 4, 37–47 (2002). https://doi.org/10.2165/00128072-200204010-00005
Published:
Issue Date:
DOI: https://doi.org/10.2165/00128072-200204010-00005